Back to top
more

Cerus (CERS)

(Delayed Data from NSDQ)

$1.81 USD

1.81
1,522,552

-0.03 (-1.63%)

Updated May 28, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CERS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cerus Corporation [CERS]

Reports for Purchase

Showing records 41 - 60 ( 69 total )

Company: Cerus Corporation

Industry: Medical - Products

Record: 41

12/16/2013

Daily Note

Pages: 8

Encouraged by 1st US Commercial Hires - Brings Insight into ARC, Largest Potential Customer

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 42

10/30/2013

Daily Note

Pages: 10

In-line 3Q13 Top Line - Key Platelet Submission & Commercial Plans on Track - Red Blood Cell Trial Results Delayed - Maintaining OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 43

10/25/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct. 28

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 44

10/24/2013

Daily Note

Pages: 7

UK Validation is Very Encouraging - Represents 1st Step Towards Widespread Use in Large Untapped Geography - Dec. SaBTO Meeting is Key - Reaffirm OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 45

10/23/2013

Company Report

Pages: 7

Optimistic into 3Q13 Call - EU Tone Sounding Better than Usual-Expecting Continued FDA Progress - Maintain OP

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 46

09/29/2013

Company Report

Pages: 7

Upping Price Target from $6 to $7.50 on Greater Scarcity Value Post Recent Viral Outbreaks and Higher Valuation Umbrella

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 47

08/15/2013

Industry Report

Pages: 15

Life Sciences Management Access Conference

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 48

07/31/2013

Company Report

Pages: 12

2Q13 Recap - Results Ok -Revs In line and 2013 Guidance Reiterated

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 49

07/26/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 50

07/22/2013

Company Report

Pages: 8

2Q13 Preview - Expecting Ok Results and Good Progress Toward FDA Submission - Minimal 2013 Guidance Risk - Reaffirm OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 51

05/01/2013

Company Report

Pages: 12

1Q13 Recap - Results Fine - Rev Guidance Reiterated - Higher Burn Understandable in Front of FDA Submissions - Reaffirm OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 52

04/29/2013

Company Report

Pages: 9

Upping Price Target to $6 from $5 Following Further FDA Clarity on Platelets

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 53

02/28/2013

Company Report

Pages: 13

4Q12 Recap - Extremely Positive Surprise as FDA Agrees to Look At Platelets

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 54

02/27/2013

Company Report

Pages: 8

4Q12 Preview - Expecting Solid Base Business - FDA Plasma Submission and Platelet Discussions in Focus - Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 55

11/07/2012

Company Report

Pages: 11

3Q12 Results Positive - Surprising Sea Change with FDA Is Very Positive

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 56

10/29/2012

Company Report

Pages: 8

3Q12 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 57

08/06/2012

Company Report

Pages: 11

2Q12 Recap - Solid Sales Considering French Rebalance & Fx Headwind - GMs Improve - Guidance Reaffirmed - RBC Programs On Track - Maintain OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 58

08/01/2012

Company Report

Pages: 7

2Q12 Preview - Expecting Solid Results - Macro & Cash Needs Weighing on Stock - Optimistic on Asian

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 59

04/30/2012

Company Report

Pages: 8

1Q12 Shaping Up Solidly - Strong French Production in Quarter,

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Cerus Corporation

Industry: Medical - Products

Record: 60

02/29/2012

Company Report

Pages: 13

Strong 4Q11 Results

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 50.00

Research Provided by a Third Party